Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.99% | 185.66% | 187.12% | 215.98% | 183.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.99% | 185.66% | 187.12% | 215.98% | 183.74% |
| Cost of Revenue | 23.34% | -11.23% | -21.80% | -25.39% | -30.27% |
| Gross Profit | 3.50% | 1,767.75% | 645.46% | 398.67% | 256.73% |
| SG&A Expenses | 6.13% | 14.42% | 41.52% | 45.93% | 42.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.28% | 2.21% | 7.88% | 5.87% | -0.62% |
| Operating Income | -15.20% | 134.97% | 110.57% | 102.91% | 81.26% |
| Income Before Tax | -77.12% | 75.27% | 58.36% | 55.68% | 63.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.12% | 75.27% | 58.36% | 55.68% | 63.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.12% | 75.27% | 58.36% | 55.68% | 63.75% |
| EBIT | -15.20% | 134.97% | 110.57% | 102.91% | 81.26% |
| EBITDA | -15.37% | 135.07% | 110.63% | 102.97% | 81.28% |
| EPS Basic | 17.77% | 89.21% | 73.80% | 70.22% | 71.60% |
| Normalized Basic EPS | 47.78% | 102.95% | 85.75% | 80.27% | 71.64% |
| EPS Diluted | 19.46% | 88.06% | 72.79% | 69.37% | 70.90% |
| Normalized Diluted EPS | 49.79% | 101.12% | 84.12% | 78.89% | 70.50% |
| Average Basic Shares Outstanding | 54.23% | 81.71% | 78.37% | 77.01% | 77.68% |
| Average Diluted Shares Outstanding | 48.22% | 86.65% | 83.83% | 83.21% | 84.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |